Introduction {#s0005}
============

Erythema dyschromicum perstans (EDP) is a disorder of pigmentation that is characterized by gray or blue-brown macules or patches in individuals with Fitzpatrick skin types III-V ([@bb0040]). The lesions are usually distributed symmetrically on both sun- and non-sun-exposed areas including the trunk (69.1%), limbs, neck, and face. EDP is a chronic progressive disorder that can present similarly to several other pigmentation disorders, such as lichen planus pigmentosus (LPP), and thereby result in difficulties to establish a diagnosis and treatment ([@bb0065]).

EDP was first noted in 1957 by [@bb0120], who described a total of 139 patients in El Salvador with progressive, ash-colored macules and patches on the trunk, arms, and legs, and whom the researchers labeled "los cencientos," or the ashen ones. On histology, a vacuolar liquefactive degeneration of the basal cell layer with dermal melanosis and a perivascular infiltrate was observed. This condition was later named ashy dermatosis. In 1961, [@bb0055] reported 5 patients in Venezuela with similar clinical symptoms, except for raised erythematous borders, which disappeared after several months. These authors named this condition EDP, with an emphasis on the erythematous margin of the active lesions. Since then, several authors have attempted to determine whether EDP is a unique entity or within a spectrum of other dyschromias, such as LPP ([@bb0030], [@bb0075]). Overall, there is now consensus that EDP and ashy dermatosis refer to different stages of the same condition ([@bb0175]).

The exact etiology of EDP is unknown. Damage to melanocytes and basal cell keratinocytes that is observed with EDP is postulated to be due to an abnormal immune response to antigens with a predominance of CD8 + T lymphocytes in the dermis and HLA-DR +, intercellular adhesion molecule 1 + keratinocytes in the epidermis ([@bb0015], [@bb0110]). A genetic susceptibility conferred by genes located in the major histocompatibility complex (mostly HLA-DR4) has also been described ([@bb0060]). In one study, patch testing was used to identify possible triggers of EDP and other dyschromias, such as LPP and pigmented contact dermatitis. The study results showed that 40% of patients with a clinical provisional diagnosis of EDP and 36% of patients with a provisional diagnosis of LPP had a positive patch test ([@bb0145]).

Despite the growing body of literature on EDP since 1957, there are no treatments that are consistently effective ([@bb0050]). In our case report, we describe a patient with EDP who was successfully treated using narrow-band ultraviolet B (NB-UVB) with sustained resolution at a long-term follow up of 4 years. In our systematic review, we investigate whether histology can be used to differentiate LPP from EDP, and summarize reported treatment outcomes and side effects.

Case report {#s0010}
===========

We report the case of a 17-year-old male patient with Fitzpatrick skin type IV who had a 1.5 year history of widespread, symmetric, brown-gray, ovoid macules and patches on the lower back that extended to his superior buttocks; some areas had erythematous rims and were associated with mild pruritus ([Fig. 1](#f0005){ref-type="fig"}A). Oral and nasal mucosa as well as the palms, soles, scalp, and nails were normal. A diagnosis of EDP was made by using the following clinical and histopathologic criteria: (i) eruption of multiple blue-gray macules or patches in typical distribution; (ii) histopathologically compatible with EDP; and (iii) absence of pigmentation-related, underlying diseases and drug history. There was no history of similar skin lesions and no personal or family history of autoimmune diseases or thyroid disease. The patient was otherwise a healthy man with no history of sexually transmitted diseases, medications, long-term use of cosmetics, or other topical products to the skin. He also did not have any history of photosensitivity or worsening skin lesions with natural sun exposure. A skin biopsy was performed and the test results indicated mild interface dermatitis with dermal melanophages ([Fig. 2](#f0010){ref-type="fig"}).Fig. 1Erythema dyschromicum perstans treated with narrow-band-ultraviolet B. (A) A 17-year-old male patient with a 1.5 year history of hyperpigmented macules and patches with areas of peripheral erythema on the lower back and buttocks that was refractory to several topical treatments. (B) Significant improvement of hyperpigmentation and erythema after 2 months of narrow-band ultraviolet B. Patient was satisfied with the results as hyperpigmentation and erythema improved and stopped progressing. Further treatment was not continued when the patient relocated to another state.Fig. 1Fig. 2Erythema dyschromicum perstans biopsy specimen of the right lower back (0.4 cm punch of skin with depth of 0.5 cm; hematoxylin and eosin × 40 magnification), showing pigment incontinence with mild interface dermatitis and perivascular lymphocytic infiltrate in dermis. The periodic acid-Schiff stain was negative for fungi and basement-membrane thickening. The colloidal iron stain demonstrated a normal amount of dermal mucin.Fig. 2

The patient was initially treated with triamcinolone, topical dapsone, clobetasol, and tacrolimus. He used different combinations of these topical medications for 6 weeks without improvement. He had also previously tried topical antifungal treatments and fluocinonide without response. NB-UVB was initiated at 300 mJ three times a week and increased by 10% to 15% per session as tolerated. The patient continued to use topical clobetasol and tacrolimus. After 2 months of NB-UVB therapy, the patient experienced a resolution of the erythema and pruritus and a significant decrease in hyperpigmentation of his lesions ([Fig. 1](#f0005){ref-type="fig"}B). The patient was satisfied with the results and did not require any further treatment. The patient has been in remission for 4 years.

Materials and methods {#s0015}
=====================

Protocol and registration {#s0020}
-------------------------

The systematic literature review was registered and conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analysis criteria.

Research strategy {#s0025}
-----------------

Using our search strategy, we queried ("erythema" and "pigmentation disorders\" or "Hyperpigmentation") or (\"Erythema dyschromicum perstans\") or (\"Erithema dyschromicum perstans\") or (\"Ashy dermatosis\") or (\"dermatosis cenicienta\") or ("blue and gray and hyperpigmentation") in four databases (PubMed, EmBase, Cochrane, and Web of Science) up to July 2017 (Search Addendum). We identified a total of 871 records. Non-human studies and languages other than English were excluded. All references identified were imported into Endnote and duplicates removed, which resulted in 659 remaining records.

Eligibility criteria and study selection {#s0030}
----------------------------------------

Two authors (MO and NL) examined 659 titles and abstracts independently (Suppl. Fig.). Articles that had a well-established etiology causing hyperpigmentation other than EDP (i.e., systemic causes such as mastocytosis; endocrine diseases such as Addison; auto-immune disorders such as lichen amyloidosis; infection such as syphilis; malignancy such as cutaneous T-cell lymphoma; and drug-related causes such as amiodarone-inducing hyperpigmentation) were excluded. The remaining 127 full-text articles were screened. Full texts that included cases of patients with another cutaneous disorder in addition to EDP were excluded to eliminate confusion of histopathologic presentations and treatment outcomes. Full texts that did not discuss histopathology results or treatment outcomes of EDP were excluded from the analysis. Ultimately, four studies on histopathology and 16 articles on treatment that met our criteria were analyzed ([Tables 1](#t0005){ref-type="table"} and [2](#t0010){ref-type="table"}).Table 1Histopathologic presentation of erythema dyschromicum perstansTable 1Lead author, year, countryStudy size (n)ResultsSoter, 1969, USA4• Melanophages\
• Liquefaction degeneration in the basal and lower spinous cellular layers\
• Perivascular infiltration of cells in the papillary dermis\
• Large translucent areas devoid of cytoplasmic organelles surrounded the nuclei, with indented nuclear envelopeVega, 1992, Mexico31 (20 EDP, 11 LPP)• Melanophages (100% for EDP vs. 100% for LPP)\
• Basal vacuolization (85% for EDP vs. 91 % for LPP)\
• Hyperkeratosis (80% for EDP vs. 91% for LPP)\
• Thinned epidermis (65% for EDP vs. 81% for LPP)\
• Lymphohistiocytic infiltrate (perivascular; 95% for EDP vs. 91% for LPP)Vasquez-Ochoa, 2006, Colombia43• Melanophages (100%)\
• Lymphohistiocytic infiltrate (100%)\
 • Perivascular in 86% of patients, diffuse in 9%, and band-like in 5%\
• Basal vacuolization (58%)Chang, 2015, Korea68• Melanophages (83.8%)\
• Lymphohistiocytic infiltrate (73.5%)\
• Band-like lymphocytic infiltration (19.1%)\
• Basal vacuolization (48.5%)[^1]Table 2Treatment outcomes in erythema dyschromicum perstansTable 2TreatmentDoseLead author (year)No. treatedSkin colorResults (+, 0, --)[⁎](#tf0005){ref-type="table-fn"}Length of RemissionSide effectsClofazimine\< 40 kg: 100 mg orally, alternative daysPiquero-Martin, 19898I-V+ (7 of 8 patients with improvement)n/a7 of 8 patients with side effects of reddish hue of skin, epigastralgia, xerosis cutis\> 40 kg: 100 mg/d 3m, then decreased to 200 mg/wk or 400 mg/wk, according to weight, 3-8m total100 mg/d, 3 mBaranda, 19976n/a+n/a2 patients removed from study. Reddish-orange skin, pruritusCorticosteroidPrednisone, oral, 3 weeksOsswald, 20011n/a+ (Resolved erythema at 1 month; partial fading of blue-gray discoloration at 3 months)n/an/aDapsone100 mg/day for 8-12 weeksKontochristopoulos, 19982n/a+ (8 and 12 weeks, no new lesions, regression of prior lesions)6 monthsRecurred after discontinuation100 mg/d, 3 monthsBahadir, 20041n/a+n/an/aGriseofulvinn/aBerger, 19891n/a+n/aRecurred after discontinuationLow potency topical steroid and hydroquinone 4%Twice dailyMunoz, 20111Vn/an/an/aLaser •Non-ablative 1550 nm FLT alone0.17 kJ (mean) energy per treatment, 5 treatments, 3 week intervalsKroon, 20128II-V-- (at 3 months)NonePIH •Non-ablative 1550 nm FLT with intermittent triple topical therapy cream (hydroquinone 5%, tretinoin 0.05%, triamcinolone 0.1%)4.1 (mean) treatments, pulse energy-15 mJ/ microbeam, 0.17 kJ (mean) energy per treatment, 3 monthsWind, 20126III, IV-- (at 3 months)NonePIH •Ablative 10,600 nm FLT with intermittent triple topical therapy cream (hydroquinone 5%, tretinoin 0.05%, triamcinolone 0.1%)2.7 (mean) treatments, pulse energy- 10 mJ/microbeam, 3 mWind, 20126III, IV-- (at 3 months)NonePIH, fibrosis •1550-nm erbium FLT and tacrolimus 0.1% ointment4.65-4.91 kJ, 5 sessions, 4-6 week intervals; 5 months; 400-525 μm depth, targets pigment in epidermis and papillary dermis; daily ointmentWolfshohl, 20171IV+8 monthsMild erythema and edema •Q-switched ruby lasern/aImanishi, 2011 (unilateral EDP)2n/a0Nonen/aTacrolimus 0.1% ointmentTwice dailyMahajan, 20152n/a+2mn/aIsotretinoinLow-dose for 7 years; required maintenance at 10 mg/dWang, 20161n/a+n/aRecurred after discontinuation; dry skinUVB3 times/week for 4 weeks, total dose 4716 mJ/cm^2^Fabbrocini, 20152n/a+n/an/aUVB and sunlightn/aTlougan, 20101n/a+n/an/aSunlightn/aAntonov, 20151IV+ (Found improved at 6 years follow up)n/an/a[^2][^3]

Outcomes {#s0035}
--------

Treatment outcomes data that were retrieved included (1) improvement, no change, or worsened clinical presentation; (2) adverse events such as postinflammatory hyperpigmentation (PIH), severe skin irritation, pruritus, or erythema; and (3) length of remission or follow up of EDP. Since heterogeneity and subjectivity rendered an analysis of the results difficult, we devised a simple scale of --1 to 1 where (--1) = side effects; (0) = no effects; and (1) = improvement. Our primary histopathologic outcomes included presence, absence, and percentages of melanophages, lymphocytic infiltrate, basal vacuolization, and hyperkeratosis. We retrieved data on study size of all studies and case reports.

Result {#s0040}
======

Histopathological presentation of erythema dyschromicum perstans {#s0045}
----------------------------------------------------------------

We found four studies on histopathologic and ultrastructural presentation of EDP. The author, publication year, study size, and results are shown in [Table 1](#t0005){ref-type="table"}. The earliest study to characterize the histologic changes of EDP dates back to 1969. [@bb0135] evaluated the ultrastructural changes in four patients with presumed EDP and observed that all patients presented with characteristic ultrastructural changes: widening of the intercellular spaces, desmosome retraction, vacuolar changes, membrane-free clear spaces in both basal and spinous cells, discontinuity of the basal lamina, and dermal melanophages. These ultrastructural changes, when individually analyzed, are nonspecific, but together provide a consistent ultrastructural indication of EDP. No additional ultrastructural studies were subsequently published to support these findings. In 1992, Vega et al. analyzed and compared the histopathologic features between EDP and LPP in 31 patients in Mexico (n = 20 for EDP; n = 11 for LPP). Due to the significant overlap in features, the authors concluded that EDP and LPP are two different clinical conditions with non-differentiable histopathologic findings.

In 2006, [@bb0155] analyzed the clinical and histologic findings of EDP in 43 patients in Colombia, and found that 100% of patients had melanophages and dermal lymphocytic infiltrate and 58% had basal vacuolization, in contrast with the 85% found by [@bb0160]. Unlike others, these authors suggest that histopathology could aid in differentiating between EDP and LPP. Most recently, in 2015, [@bb0040] conducted a retrospective study of 68 patients with EDP from six tertiary centers in Korea between 2002 and 2012 and found an 83.8% prevalence of melanophages and 73.5% of lymphocytic infiltrate, which is lower than previously described.

Taken together, these four studies demonstrate that melanophages and lymphocytic infiltrate are present in nearly all patients with EDP, and basal vacuolization is present in more than half of the patients. Furthermore, EDP and LPP were found to have significant overlap in histology.

Treatment outcomes in erythema dyschromicum perstans {#s0050}
----------------------------------------------------

Sixteen articles on the treatment of EDP were found. Author, publication year, treatment used, dose, Fitzpatrick skin type, treatment outcome, length of remission, and adverse outcomes are noted in [Table 2](#t0010){ref-type="table"}. One of the earliest treatments published on was clofazimine. In a study from 1989, 7 of 8 patients treated with clofazimine obtained a good-to-excellent response, but all experienced side effects such as discoloration of the skin, xerosis cutis, and epigastralgia ([@bb0115]). Later, another study reported significant improvement in 4 of 6 patients treated, where 2 patients dropped out of the study (one due to intolerable side effects; [@bb0015]). Furthermore, discerning whether the discoloration of the skin was camouflaging the lesions was difficult. Dapsone led to improvement; however, lesions recurred after discontinuation of use in one of three cases ([@bb0010], [@bb0095]). Likewise, griseofulvin helped temporarily, but lesions recurred after discontinuation in one patient ([@bb0020]).

The most promising topical treatment at this time is tacrolimus. Tacrolimus is a macrolide antibiotic medication with immunosuppressive properties, exerting its effects principally through the inhibition of calcium-dependent events such as the interleukin (IL) 2 gene transcription, nitric oxide synthase activation, cell degranulation, and apoptosis ([@bb0140]). Tacrolimus was described with success in the treatment of EDP either as a monotherapy or in combination with laser ([@bb0105]) and, in our case, with NB-UVB. NB-UVB has been successfully used to treat EDP in three case reports including our case, all with minimal to no side effects ([@bb0070], [@bb0150]). One case presented a patient with a resolution of EDP after a prolonged period of intense sun exposure ([@bb0005]). Our report notes the longest of any follow-up period of EDP after treatment and demonstrates sustained resolution.

The treatment of EDP with fractional lasers have largely been unsuccessful and in several occasions were associated with postinflammatory pigmentation changes. Q-switched lasers have been used with ineffective results in two patients ([@bb0090]). In 2012, [@bb0165] compared non-ablative with ablative fractional laser therapy in a randomized-controlled observer-blinded study in 6 patients with EDP. Both methods were ineffective and caused PIH. Fibrosis also developed with ablative fractional laser.

In a randomized, controlled, observer-blinded study in 2012, [@bb0100] treated 8 patients with non-ablative 1550 nm fractional laser therapy (FLT). Three months after the last treatment, an improvement of hyperpigmentation was assessed with melanin index, reflectance spectroscopy, physician's assessment, patient assessment, and patient satisfaction. No clinical improvement of hyperpigmentation was observed, but PIH occurred and patients considered FLT unsatisfactory. The only case of EDP that was successfully treated using laser was in 2017, as reported by [@bb0170] In this study, a patient was successfully treated with a combination of monthly treatments of 1550-nm erbium-doped, fractionated laser and topical tacrolimus over a period of 5 months. The success of the treatment was hypothesized to be secondary to the laser settings and the additive effect of tacrolimus.

Comparison of erythema dyschromicum perstans and lichen planus pigmentosus {#s0055}
--------------------------------------------------------------------------

Studies by [@bb0045] and [@bb0160] compared LPP and EDP. EDP is more likely than LPP to have a generalized distribution and erythema at the time of onset ([Table 3](#t0015){ref-type="table"}). [@bb0160] noted that EDP presents with blue-gray or ashy hyperpigmented macules whereas LPP presents with dark brown, more irregularly shaped, and ill-defined macules. Patients with LPP most commonly have localized face and neck lesions, but EDP presents with lesions in more than one location and most commonly on the upper extremities, face, neck, and trunk. [@bb0160] emphasized that lesions in LPP are either on sun-exposed areas such as the face and neck or, when on the trunk, only present in flexural areas. This finding was supported by [@bb0045] in their conclusions. They further specified that LPP generally originates symmetrically at the temples or pre-auricular locations. EDP generally has predominance in female patients, but no sexual predominance in LPP has been identified. EDP occurred at a younger average age (33.6 years in the study by [@bb0160]; 38.8 years in the study by [@bb0045]) compared with LPP (46 years for Vega et al.; 42.7 years for Cheng et al.), although both can occur in children and adults. Both studies concluded that EDP and LPP do not have significant differences in histopathology. Treatments for these patients were not detailed in either study, but topical medications were infrequently and inconsistently effective to treat EDP and LPP.Table 3Comparison of erythema dyschromicum perstans and lichen planus pigmentosusTable 3Patient characteristicsClinical morphologyDistributionPathologyTreatment options**EDP**Female predominance; intermediate to dark skin typesBlue-gray or ashy-brown macules\
Erythematous rash prior/active red border in someMore likely to be widespread with truncal predominance but can involve face, neck, arms, legsHyperkeratosis, thinned epidermis, basal vacuolization, perivascular infiltrate, melanophages presentTopical corticosteroid\
Topical tacrolimus\
Narrowband UVB\
Oral dapsone**LPP**No sexual predominance\
Darker skin types (more frequently found in patients of Indian descent)Dark brown irregularly shaped and ill-defined maculesMore likely to be localized to the face and neck (sun-exposed areas)\
Often starts on temples and preauricular area\
Flexural areas can be involvedHyperkeratosis, thinned epidermis, basal vacuolization, perivascular infiltrate, melanophages presentTopical corticosteroid\
Topical tacrolimus\
Photo-protection/sun avoidance\
Topical tretinoin\
Low dose isotretinoin\
Oral dapsone[^4]

Discussion {#s0060}
==========

We conducted a systematic review of the literature on EDP up to July 2017 to summarize data on the histologic presentation and treatment outcomes of EDP. Our findings demonstrate that histology has its role in differentiating EDP from other disorders that can present with hyperpigmentation, such as mycosis fungoides, pigmented contact dermatitis, syphilis, mastocytosis, drug-induced hyperpigmentation, or postinflammatory pigmentation changes. However, because the histologic presentation was found to have a significant overlap between EDP and LPP, we recommend that histology alone must not be used to differentiate these entities. Clinical history, morphology, and distribution should instead be used to differentiate EDP and LPP.

LPP is largely localized to photo-exposed areas of the face and neck, and photo-aggravation was identified as a precipitating cause of LPP in 12 of 16 patients ([@bb0025]). This is in contrast to EDP, which is not limited to photo-exposed areas and improves with light therapy. With regard to treatment, our findings suggest that NB-UVB and tacrolimus were effective therapies to treat EDP with minimal side effects ([@bb0035], [@bb0085]). Studies in a larger patient population are needed to confirm this data. No evidence of postinflammatory pigmentation changes was observed in our patient who substantially improved with NB-UVB. Of note, the use of UVB, either via natural sunlight exposure or NB-UVB, was reported to improve EDP. This is in contrast with LPP where sunlight appears to have a causative effect, which suggests these may be separate entities with different pathophysiology ([@bb0125]).

Studies on the subpopulation of immune cells in patients with EDP indicate a dermal lymphocytic infiltrate of predominantly CD8 + T lymphocytes, with an upregulation of intercellular adhesion molecules 1 + and macrophages adjacent to extracellular melanin pigment ([@bb0080]). Both NB-UVB and tacrolimus may be effective to treat EDP due to their immunomodulatory effect on T cells and suppression of proinflammatory cytokines, including tumor necrosis factor-alpha, IL-17A, IL-6, IL-1, and IL-8 in the epidermis and upper part of the papillary dermis ([@bb0130]).

Conclusion {#s0065}
==========

In our review, we found that EDP and LPP overlap significantly in their histologic presentation. We recommend using clinical history, morphology, and distribution to differentiate EDP from LPP, and histology can be used to rule out other etiologies. EDP lesions are more likely to be generalized and located on the trunk, upper extremities, face, and neck. LPP lesions generally originate near the temples and pre-auricular areas of the face and are localized to photo-exposed areas such as the face and neck. In LPP, when lesions are present on areas other than the face and neck, lesions are likely in flexural areas. EDP presents with blue-gray, regularly shaped, hyperpigmented macules compared with dark brown, irregularly shaped, and ill-defined hyperpigmented macules in LPP. EDP was more likely to present with erythematous raised active borders than LPP.

We conclude for EDP, NB-UVB and tacrolimus are promising and effective treatments with significantly fewer side effects compared with clofazimine, and opposed to LPP, for which sun-avoidance is recommended. Treatment with isotretinoin, dapsone, and griseofulvin led to the recurrence of EDP after discontinuation of these drugs in several cases. Lasers were consistently ineffective treatments. The histopathologic description of EDP presentation was consistent across four studies, but treatment outcome data were largely limited to case reports and studies with a maximum of 8 patients in each study, which indicates that larger studies to evaluate treatment outcomes are needed.

Appendix A. Supplementary data {#s0070}
==============================
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[^1]: EDP, erythema dyschromicum perstans; LPP, lichen planus pigmentosus

[^2]: EDP, erythema dyschromicum perstans; FLT, fractional laser therapy; LPP, lichen planus pigmentosus; PIH, postinflammatory hyperpigmentation; UVB, ultraviolet B

[^3]: \+ means improved; 0 means no effects; -- means worsened; None indicates noted to have none; and n/a means was not noted.

[^4]: EDP, erythema dyschromicum perstans; FLT, fractional laser therapy; LPP, lichen planus pigmentosus; UVB, ultraviolet B
